A Randomized, Double-blind, Placebo-controlled Clinical Study of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate, Administered to Patients With Rheumatoid Arthritis to Determine Safety, Tolerability, Pharmacokinetic and Synovial Tissue Outcomes

Clinical trial NCT00642629 · COMPLETED

Trial details

NCT number: NCT00642629
Sponsor: Synta Pharmaceuticals Corp.
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Active, Moderate to Severe Rheumatoid Arthritis

Start date: 2005-12-01
Enrollment: 35

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.